Edwards Lifesciences Corporation (VIE:EWLS)

Austria · Delayed Price · Currency is EUR

75.41

+2.27 (3.10%)

At close: Dec 5, 2025

Revenue

Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2013 - 2020
Transcatheter Aortic Valve Replacement Revenue	4.36B	4.11B	Log In	Log In	Log In	Upgrade
Transcatheter Mitral and Tricuspid Therapies Revenue	500.00M	352.10M	Log In	Log In	Log In	Upgrade
Surgical Structural Heart Revenue	1.02B	981.30M	Log In	Log In	Log In	Upgrade
Critical Care Revenue	-	-	Log In	Log In	Log In	Upgrade
Revenue (Total)	5.88B	5.44B	Log In	Log In	Log In	Upgrade

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	2013 - 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2013 - 2020
United States Revenue	3.45B	3.21B	Log In	Log In	Log In	Upgrade
Europe Revenue	1.45B	1.32B	Log In	Log In	Log In	Upgrade
Japan Revenue	353.10M	339.80M	Log In	Log In	Log In	Upgrade
Rest of World Revenue	630.10M	572.00M	Log In	Log In	Log In	Upgrade
Revenue (Total)	5.88B	5.44B	Log In	Log In	Log In	Upgrade